Report Adverse Event or Product Quality Complaint    US Site     Global Site

AZmedical Information Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ASN 2026

American Society of Nephrology (ASN) Kidney Week 2026

October 21–25, 2026

  1. All
  2. aHUS
  3. DGF
  4. HypoPT
  5. IgAN
  6. PMN

PDF

Hanna R et al. Long-term real-world effectiveness of ravulizumab among C5-inhibitor-naive patients with atypical hemolytic uremic syndrome (aHUS): a physician-panel-based chart review study (aHUS-EXTEND study) (Poster)

PDF

Azoulay E et al. Patients with atypical hemolytic uremic syndrome and intensive care unit support: analysis of a ravulizumab phase 3 study (Poster)

PDF

Memon A et al. Real-world renal outcomes among C5 inhibitor-naive patients treated with first-line ravulizumab therapy for atypical hemolytic uremic syndrome (aHUS) (Poster)

HTML

Mital J et al. Anti-C5 therapy improves kidney outcomes after donation after circulatory death kidney transplantation with static cold storage and provides additional benefit to ex vivo machine perfusion in a rat model (Abstract)

PDF

Palermo A et al. Improvements in kidney outcomes with eneboparatide in chronic hypoparathyroidism over 1 year: a phase 3, randomized, placebo-controlled and open-label study assessing the efficacy and safety of eneboparatide (CALYPSO) (Poster)

PDF

Gu Y et al. Prevalence of kidney complications at baseline in patients with chronic hypoparathyroidism: a large US claims cross-sectional study (Poster)

PDF

Gosmanova E et al. Renal outcomes and impact of inadequate disease control and hypercalciuria among patients with chronic hypoparathyroidism: a retrospective observational study (Poster)

HTML

Cammett T et al. Evidence of a rapid and localized anti-inflammatory effect of ravulizumab in IgAN: prespecified biomarker analysis of the I CAN phase 3 trial (Abstract)

PDF

Wang Y et al. Real-world adherence to oral therapies in IgA nephropathy (Poster)

PDF

Fervenza F et al. A phase 2a, randomized, double-blind, placebo-controlled, multicenter clinical trial of ALXN1920 in adults with primary membranous nephropathy (Poster)

Lafayette R et al. Effects of ravulizumab on proteinuria and hematuria in IgAN: a prespecified interim analysis of the phase 3 I CAN trial (Abstract)

PDF

Hanna R et al. Long-term real-world effectiveness of ravulizumab among C5-inhibitor-naive patients with atypical hemolytic uremic syndrome (aHUS): a physician-panel-based chart review study (aHUS-EXTEND study) (Poster)

PDF

Azoulay E et al. Patients with atypical hemolytic uremic syndrome and intensive care unit support: analysis of a ravulizumab phase 3 study (Poster)

PDF

Memon A et al. Real-world renal outcomes among C5 inhibitor-naive patients treated with first-line ravulizumab therapy for atypical hemolytic uremic syndrome (aHUS) (Poster)

HTML

Mital J et al. Anti-C5 therapy improves kidney outcomes after donation after circulatory death kidney transplantation with static cold storage and provides additional benefit to ex vivo machine perfusion in a rat model (Abstract)

PDF

Palermo A et al. Improvements in kidney outcomes with eneboparatide in chronic hypoparathyroidism over 1 year: a phase 3, randomized, placebo-controlled and open-label study assessing the efficacy and safety of eneboparatide (CALYPSO) (Poster)

PDF

Gu Y et al. Prevalence of kidney complications at baseline in patients with chronic hypoparathyroidism: a large US claims cross-sectional study (Poster)

PDF

Gosmanova E et al. Renal outcomes and impact of inadequate disease control and hypercalciuria among patients with chronic hypoparathyroidism: a retrospective observational study (Poster)

HTML

Cammett T et al. Evidence of a rapid and localized anti-inflammatory effect of ravulizumab in IgAN: prespecified biomarker analysis of the I CAN phase 3 trial (Abstract)

PDF

Wang Y et al. Real-world adherence to oral therapies in IgA nephropathy (Poster)

Lafayette R et al. Effects of ravulizumab on proteinuria and hematuria in IgAN: a prespecified interim analysis of the phase 3 I CAN trial (Abstract)

PDF

Fervenza F et al. A phase 2a, randomized, double-blind, placebo-controlled, multicenter clinical trial of ALXN1920 in adults with primary membranous nephropathy (Poster)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States